These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 31654514)

  • 1. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
    Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
    Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen.
    Sun LQ; Liu JY; He Y; Zhou Y; Xu LM; Zhang LK; Zhao F; Liu XN; Song Y; Cao TZ; Tian YM; Rao M; Wang H
    Chin Med J (Engl); 2020 Dec; 133(23):2808-2815. PubMed ID: 33273329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Parker I; Vidakovic B; Getenet H; Assefa G; Amogne W
    PLoS One; 2015; 10(4):e0117125. PubMed ID: 25915208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Rosebush JC; Shapiro AM; Schwartz MH; Eckard AR; Amogne W; Abebe W
    J Biomech; 2016 Sep; 49(13):2584-2592. PubMed ID: 27270208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
    Sierra-Madero J; Villasis-Keever A; Méndez P; Mosqueda-Gómez JL; Torres-Escobar I; Gutiérrez-Escolano F; Juárez-Kasusky I; Magana-Aquino M; Ramos-Santos C; Pérez-Saleme L; Rangel-Frausto S; Antuna-Puente B; Soto-Ramírez LE; Lima V; Belaunzarán-Zamudio F; Crabtree-Ramírez B; Montaner J
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
    Koss CA; Natureeba P; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Clark TD; Achan J; Ruel T; Nzarubara B; Kamya MR; Havlir DV; Cohan D
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):128-35. PubMed ID: 25072616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
    McDonald CR; Conroy AL; Gamble JL; Papp E; Hawkes M; Olwoch P; Natureeba P; Kamya M; Silverman M; Cohan D; Koss CA; Dorsey G; Kain KC; Serghides L
    Clin Infect Dis; 2018 Jan; 66(3):428-436. PubMed ID: 29136115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
    Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F
    Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
    Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial.
    Torres B; Rallón NI; Loncá M; Díaz A; Alós L; Martínez E; Cruceta A; Arnaiz JA; Leal L; Lucero C; León A; Sánchez M; Negredo E; Clotet B; Gatell JM; Benito JM; Garcia F
    AIDS Res Hum Retroviruses; 2014 May; 30(5):425-33. PubMed ID: 24380397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
    Shaffer D; Hughes MD; Sawe F; Bao Y; Moses A; Hogg E; Lockman S; Currier J
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):155-63. PubMed ID: 24562349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.
    Strehlau R; Coovadia A; Abrams EJ; Martens L; Arpadi S; Meyers T; Kuhn L
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):369-76. PubMed ID: 22134152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.
    Egaña-Gorroño L; Martínez E; Domingo P; Loncà M; Escribà T; Fontdevila J; Vidal F; Negredo E; Gatell JM; Arnedo M
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6717-23. PubMed ID: 25155608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
    Rojas J; Lonca M; Imaz A; Estrada V; Asensi V; Miralles C; Domingo P; Montero M; del Rio L; Fontdevila J; Perez I; Cruceta A; Gatell JM; Arnedo M; Martínez E
    HIV Med; 2016 May; 17(5):340-9. PubMed ID: 27089862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in blood lipid levels and influencing factors among treatment-naïve adult male HIV/AIDS patients following BIC/FTC/TAF vs . 3TC+EFV+TDF.
    Wang X; Liu A; Li Z; Zhang H; Wu RE; Shao Y; Li J; Ye J; Liu W; Sun L
    Chin Med J (Engl); 2024 Jun; 137(12):1447-1452. PubMed ID: 38816366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI.
    Liu S; Wei B; Liang W; Chen T; Deng L; Zhao M; Wan J
    Front Public Health; 2023; 11():1161503. PubMed ID: 37181701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.